feedback

Course Director

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA, FECMM
Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA, FECMM

The University of Texas MD Anderson Cancer Center
Baylor College of Medicine
University of Houston
Houston, Texas

Faculty

Michael Boeckh
Michael Boeckh, MD

Fred Hutchinson Cancer Research Center
University of Washington
Seattle, Washington

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2017-Mar-31
Expiration Date:2018-Mar-30
Estimated Time for Completion:60 mintues
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Hematopoietic stem cell transplant (HCT) recipients, especially those who have received allogeneic transplants, are at substantial risk for a variety of infections associated with high morbidity and mortality. The risk of these infections (eg, cytomegalovirus, invasive fungal infection) depends on the recipient’s degree of immunosuppression and exposure to pathogens, as well as the time elapsed since transplantation.

In this activity, based on a live symposium that took place at the 2017 BMT Tandem Meetings in Orlando, Florida, two experts examine evidence-based strategies to minimize the burden of infections in HCT recipients, and provide insight on the evolving approach to the prevention and management of cytomegalovirus and invasive fungal infection, with a focus on the clinical potential of new and emerging therapeutic strategies.

Upon completion of this activity, participants should be better able to:

  • Describe the risks and outcomes of cytomegalovirus (CMV) and invasive fungal infection after hematopoietic stem cell transplantation (HCT)
  • Assess the efficacy and safety of current and emerging antiviral and antifungal drugs for CMV and invasive fungal infections, respectively
  • Apply evidence-based, individualized strategies for the prevention and management of CMV and invasive fungal infection in HCT recipients, recognizing the clinical potential of new and emerging therapeutic strategies

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice hematology/oncology nurses, bone marrow transplant clinical nurse specialists, pharmacists, transplant specialists, and other clinicians who manage patients who have undergone a hematopoietic stem cell transplant.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 31, 2017 - March 30, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA, FECMM
Frances King Black Endowed Professor, Infectious Diseases
Deputy Head, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Adjunct Professor Baylor College of Medicine
Adjunct Professor University of Houston
Houston, Texas

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA, FECMM, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Astellas Pharma US, Inc.; Merck & Co., Inc.; and Pfizer Inc.
Advisory Board for Merck & Co., Inc.

Faculty

Michael Boeckh, MD
Member, Vaccine and Infectious Disease Division
Head, Infectious Disease Sciences Program
Fred Hutchinson Cancer Research Center
Professor, Department of Medicine, University of Washington
Seattle, Washington

Michael Boeckh, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma US, Inc.; Chimerix; Helocyte, Inc.; Merck & Co., Inc.; Microbiotix, Inc.; Oxford Immunotec Inc.; and Shire.
Grant/Research Support from Astellas Pharma US, Inc.; Chimerix; Merck & Co., Inc.; and Shire.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership

This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent medical educational grants from Astellas, Merck & Co., Inc., and Shire.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.


Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.